Table 4. Univariate and multivariate analysis of association of prognostic factors and N/L ratio with overall survival.
| |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| Parameter | HR (95% CI) | P-value | HR (95% CI) | P-value |
|
Sex | ||||
| Female | 1 (referent) | 0.364 | 1 (referent) | 0.035 |
| Male |
0.82 (0.53–1.26) |
|
0.62 (0.39–0.97) |
|
|
Tumour site | ||||
| Extremities | 1 (referent) | 0.877 | 1 (referent) | 0.592 |
| Trunk |
1.05 (0.54–2.04) |
|
1.21 (0.62–2.35) |
|
|
Tumour depth | ||||
| Superficial | 1 (referent) | 0.986 | 1 (referent) | 0.632 |
| Deep |
1.00 (0.60–1.65) |
|
0.88 (0.53–1.49) |
|
|
Tumour grade | ||||
| G1 | 1 (referent) | <0.001 | 1 (referent) | 0.098 |
| G2 | 2.06 (0.72–5.84) | 1.98 (0.60–6.59) | ||
| G3 |
5.78 (2.32–14.41) |
|
2.66 (0.84–8.47) |
|
|
Tumour size | ||||
| <5 cm | 1 (referent) | 0.282 | 1 (referent) | 0.381 |
| ⩾5 cm |
1.35 (0.78–2.35) |
|
1.29 (0.73–2.27) |
|
|
Tumour necrosis | ||||
| 0 | 1 (referent) | <0.001 | 1 (referent) | 0.001 |
| ⩽50% | 2.42 (1.34–4.40) | 1.47 (0.73–2.95) | ||
| >50% |
6.02 (3.36–10.78) |
|
3.00 (1.40–6.45) |
|
|
Resection margins | ||||
| Wide | 1 (referent) | 0.811 | 1 (referent) | 0.850 |
| Marginal |
0.90 (0.36–2.22) |
|
1.09 (0.43–2.76) |
|
|
Tumour stage | ||||
| Localised at diagnosis | 1 (referent) | <0.001 | 1 (referent) | 0.020 |
| Metastasised at diagnosis |
1.48 (1.22–1.80) |
|
1.29 (1.04–1.61) |
|
|
Adjuvant chemotherapy | ||||
| Yes | 1 (referent) | 0.028 | 1 (referent) | 0.505 |
| No |
1.65 (1.06–2.57) |
|
1.17 (0.74–1.87) |
|
|
Adjuvant radiotherapy | ||||
| Yes | 1 (referent) | 0.691 | 1 (referent) | 0.406 |
| No |
1.10 (0.69–1.75) |
|
0.80 (0.48–1.35) |
|
|
N/L ratio 3.58 | ||||
| <3.58 | 1 (referent) | <0.001 | 1 (referent) | 0.014 |
| ⩾3.58 | 2.90 (1.82–4.61) | 1.88 (1.14–3.12) | ||
Abbreviations: CI=confidence interval; HR=hazard ratio; N/L=neutrophil/lymphocyte.